HK Stock Market Move | PEGBIO CO-B (02565) rises nearly 5% again; Paidakang successfully included in national medical insurance, with subsequent volume ramp-up expected to accelerate.

date
09:57 17/11/2026
avatar
GMT Eight
PEGBIO CO-B (02565) rose nearly 5% again. As of press time, it was up 3.57% at HK$3.335, with a turnover of HK$21.5625 million.
PEGBIO CO-B (02565) rose nearly 5% again. As of press time, it was up 3.57% at HK$3.335, with turnover of HK$21.5625 million. On the news front, Pegbio's core product Paidakang (beinaglutide injection) has been successfully included in the 2026 National Medical Insurance Drug Catalog, marking a major commercialization milestone. Previously, Pegbio reached an exclusive commercialization partnership with Shanghai Tengrui Pharmaceutical for mainland China, setting a cumulative sales target of over RMB10 billion, with product sales revenue to be recognized by Pegbio. Public information shows that Paidakang is a once-weekly GLP-1 formulation for glycemic control in adults with type 2 diabetes. The company stated that Paidakang is the group's first approved innovative drug product, and its inclusion in the National Medical Insurance Catalog is expected to enhance patient affordability and drug accessibility, helping to advance the product's access, clinical promotion, and market coverage across medical institutions nationwide.